CLINICAL_TRIALS
trial_result
· 2023-09-08
Clinical Trial Update: Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma [Phase 2]
Summary
A Phase 2 trial evaluating the combination of MAPK-targeted therapy with pembrolizumab for metastatic melanoma has posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Massachusetts General Hospital | Conditions: Metastatic Melanoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-09-08